Insulin lispro (Lyumjev) vs insulin NPH
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline
Insulin lispro (Lyumjev)
Marketed by Eli Lilly
NCT03214380 · Phase 3 · completed
The study randomized and double-blinded participants to LY900014 or insulin lispro, with 933 enrolled and approximately 336-337 participants in the main comparison arms. The primary HbA1c endpoint met the prespecified non-inferiority margin, but HbA1c is a laboratory surrogate rather than a hard clinical endpoint, supporting a moderate evidence grade.
Reported efficacy
Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): LY900014 -0.56 Percentage of HbA1c (Standard Error 0.046) vs Insulin Lispro (Humalog) -0.63 Percentage of HbA1c (Standard Error 0.061) (met)
Result source: NCT03952143
insulin NPH · Humulin N
Marketed by Eli Lilly
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Insulin lispro (Lyumjev) | insulin NPH |
|---|---|---|
| HbA1c, change | -0.4% vs -0.4%vs Insulin Lispro (Humalog)NCT032143801 other result
| —Not posted · NCT00604396 |
| Body weight, change (kg) | —Not reported | 12.6 vs 13vs LevemirNCT01837680 |
| HbA1c below 7% | —Not reported | —Not posted · NCT00604396 |
| Fasting plasma glucose, change | —Not reported | —Not posted · NCT00604396 |
| 3-point MACE (% with event) | —Not reported | —Not posted · NCT00604396 |
HbA1c, change
- Insulin lispro (Lyumjev)
- -0.4% vs -0.4%vs Insulin Lispro (Humalog)NCT03214380
1 other result
- -0.6% vs -0.6% NCT03952143
- insulin NPH
- —Not posted · NCT00604396
Body weight, change (kg)
- Insulin lispro (Lyumjev)
- —Not reported
- insulin NPH
- 12.6 vs 13vs LevemirNCT01837680
HbA1c below 7%
- Insulin lispro (Lyumjev)
- —Not reported
- insulin NPH
- —Not posted · NCT00604396
Fasting plasma glucose, change
- Insulin lispro (Lyumjev)
- —Not reported
- insulin NPH
- —Not posted · NCT00604396
3-point MACE (% with event)
- Insulin lispro (Lyumjev)
- —Not reported
- insulin NPH
- —Not posted · NCT00604396
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Insulin lispro (Lyumjev): 4 of 4 rows · insulin NPH: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Insulin lispro (Lyumjev) | insulin NPH |
|---|---|---|
| Dropout rate | —a NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 16 more results— NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3 17.6% NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3 —LY900014 After Meal NCT03341312 · Phase 1 · registry result, not featured evidence —LY900014 Before Meal NCT03341312 · Phase 1 · registry result, not featured evidence —15 U NCT03286751 · Phase 1 · registry result, not featured evidence —30 U NCT03286751 · Phase 1 · registry result, not featured evidence —7 U NCT03286751 · Phase 1 · registry result, not featured evidence —15 U NCT03305822 · Phase 1 · registry result, not featured evidence —15 U NCT03232983 · Phase 1 · registry result, not featured evidence —15 U NCT03232983 · Phase 1 · registry result, not featured evidence —15 U NCT03232983 · Phase 1 · registry result, not featured evidence —15 U NCT03232983 · Phase 1 · registry result, not featured evidence —LY900014 - Test (Part B) NCT02703337 · Phase 1 · registry result, not featured evidence —LY900014 - Test +15 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence · combination —LY900014 - Test -15 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence —LY900014 - Test 0 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence | 19.2%b NCT01837680 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 16 more results— NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.7% NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3 —LY900014 After Meal NCT03341312 · Phase 1 · registry result, not featured evidence —LY900014 Before Meal NCT03341312 · Phase 1 · registry result, not featured evidence —15 U NCT03286751 · Phase 1 · registry result, not featured evidence —30 U NCT03286751 · Phase 1 · registry result, not featured evidence —7 U NCT03286751 · Phase 1 · registry result, not featured evidence —15 U NCT03305822 · Phase 1 · registry result, not featured evidence —15 U NCT03232983 · Phase 1 · registry result, not featured evidence —15 U NCT03232983 · Phase 1 · registry result, not featured evidence —15 U NCT03232983 · Phase 1 · registry result, not featured evidence —15 U NCT03232983 · Phase 1 · registry result, not featured evidence —LY900014 - Test (Part B) NCT02703337 · Phase 1 · registry result, not featured evidence —LY900014 - Test +15 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence · combination —LY900014 - Test -15 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence —LY900014 - Test 0 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence | —b NCT01837680 · Phase na · registry result, not featured evidence |
| Serious AEs | 7.7%a NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 16 more results8.4% NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.7% NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3 0%LY900014 After Meal NCT03341312 · Phase 1 · registry result, not featured evidence 0%LY900014 Before Meal NCT03341312 · Phase 1 · registry result, not featured evidence 0%15 U NCT03286751 · Phase 1 · registry result, not featured evidence 0%30 U NCT03286751 · Phase 1 · registry result, not featured evidence 0%7 U NCT03286751 · Phase 1 · registry result, not featured evidence 0%15 U NCT03305822 · Phase 1 · registry result, not featured evidence 0%15 U NCT03232983 · Phase 1 · registry result, not featured evidence 0%15 U NCT03232983 · Phase 1 · registry result, not featured evidence 0%15 U NCT03232983 · Phase 1 · registry result, not featured evidence 0%15 U NCT03232983 · Phase 1 · registry result, not featured evidence 0%LY900014 - Test (Part B) NCT02703337 · Phase 1 · registry result, not featured evidence 0%LY900014 - Test +15 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence · combination 0%LY900014 - Test -15 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence 0%LY900014 - Test 0 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence | 0%b NCT01837680 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | a nasopharyngitis 14% upper respiratory tract infection 8% diarrhoea 3.3% NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 15 more resultsupper respiratory tract infection 5.3% NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3 injection site reaction 5.6% NCT03341312 · Phase 1 · registry result, not featured evidence injection site reaction 2.9% NCT03341312 · Phase 1 · registry result, not featured evidence 15 U headache 10% nausea 5% injection site reaction 2.5% NCT03286751 · Phase 1 · registry result, not featured evidence 30 U headache 14.6% injection site reaction 14.6% nausea 7.3% NCT03286751 · Phase 1 · registry result, not featured evidence 7 U headache 15% injection site reaction 2.5% nausea 2.5% NCT03286751 · Phase 1 · registry result, not featured evidence 15 U headache 5.3% vessel puncture site thrombosis 5.3% NCT03305822 · Phase 1 · registry result, not featured evidence 15 U infusion site pain 12% catheter site bruise 8% vessel puncture site bruise 8% NCT03232983 · Phase 1 · registry result, not featured evidence 15 U injection site pain 11.5% application site erythema 7.7% catheter site bruise 7.7% NCT03232983 · Phase 1 · registry result, not featured evidence 15 U catheter site pain 10.7% catheter site swelling 7.1% application site erythema 3.6% NCT03232983 · Phase 1 · registry result, not featured evidence 15 U catheter site bruise 7.7% infusion site erythema 7.7% infusion site swelling 7.7% NCT03232983 · Phase 1 · registry result, not featured evidence headache 6.7% back pain 0% thrombophlebitis 0% NCT02703337 · Phase 1 · registry result, not featured evidence back pain 0% headache 0% thrombophlebitis 0% NCT02703337 · Phase 1 · registry result, not featured evidence · combination thrombophlebitis 6.9% back pain 0% headache 0% NCT02703337 · Phase 1 · registry result, not featured evidence thrombophlebitis 10.3% back pain 0% headache 0% NCT02703337 · Phase 1 · registry result, not featured evidence | b biochemical event of hypoglycemia 26.9% symptomatic hypoglycemia 21.2% rash 11.5% NCT01837680 · Phase na · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 14 of these studies.
- bPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Insulin lispro (Lyumjev)
show 1 more result
+ 8 further endpoints in the CSV export.
insulin NPH
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin lispro (Lyumjev)'s landscape · insulin NPH's landscape